RGS16 Antibody (YA7951)

RGS16 (Regulator of G-protein Signaling 16) is a member of the R4 subfamily of RGS proteins that accelerates GTP hydrolysis on Gα subunits and thereby terminates or constrains GPCR signaling outputs^[1][2]. Mechanistically, RGS16 regulates classical GPCR pathways and also influences downstream signaling networks including MAPK, PI3K/Akt, RhoA, and SDF-1/CXCR4 pathways, linking receptor activation to immune, inflammatory, metabolic, and tumor-associated biological processes^[1]. In metabolic models, hepatic RGS16 expression is induced during gluconeogenic states and provides a mechanism through which glucose production suppresses GPCR-stimulated fatty-acid oxidation, highlighting a role in energy homeostasis^[3]. In pancreatic islets, RGS16 functions as a regulator of β-cell physiology by attenuating inhibitory Gα_i/o-dependent somatostatin signaling, thereby promoting cAMP accumulation, insulin secretion, and β-cell proliferation in both rodent and human systems^[4]. RGS16 also contributes to circadian regulation, where it is required for cAMP control within the suprachiasmatic nucleus and is linked to GPCR-mediated clock signaling mechanisms^[5]. Compared with related RGS isoforms, RGS16 belongs to the small R4 family but displays distinct G-protein selectivity and signaling interactions that contribute to nonredundant biological functions across tissues^[2]. For experimental applications, modulation of RGS proteins is widely explored as a strategy to control GPCR signal transduction, making RGS16 a useful target for mechanistic studies of metabolism, immunity, circadian biology, and disease-associated signaling networks^[1][6].